Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Core Insights - Eli Lilly and Company has successfully completed the acquisition of Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease [1] - The acquisition is expected to transform treatment paradigms for millions of patients by providing lifelong cardiovascular risk reduction through a single treatment [2] Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, helping tens of millions globally with its medicines [2] - The company is focused on addressing significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [2] Strategic Implications - The integration of Verve Therapeutics is anticipated to enhance Lilly's capabilities in developing innovative genetic medicines for cardiometabolic diseases [2] - The acquisition aligns with Lilly's mission to make life better for millions by advancing clinical trials and ensuring medicine accessibility [2]